Category - Executive Moves

Executive Moves

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Tom Civik Five Prime Therapeutics (NASDAQ:FPRX) appointed Tom Civik as president, CEO and a director. William Ringo, who served as Five Prime’s chairman and interim CEO since September 2019, will step down as CEO and...

April 14, 2020

Executive Moves

Akcea names Damien Devitt as CEO

Damien Devitt, who has been interim CEO of Akcea Therapeutics (NASDAQ:AKCA) since September 2019, has been promoted to CEO, effective immediately, and will continue to serve as a member of Akcea’s board. “With his...

March 24, 2020

Executive Moves

Covetrus names Benjamin Wolin as CEO

Benjamin Wolin Benjamin Wolin, who has been acting CEO of Covetrus (NASDAQ:CVET) since October 2019, has been promoted to president and CEO, effective immediately. Covetrus was formed in February 2019 as the result of a...

March 4, 2020

Executive Moves

BioSig appoints John Osborn as consultant on autonomic neuromodulation

BioSig Technologies (NASDAQ:BSGM) signed a consulting agreement with John Osborn, Prof. in the Department of Surgery and director of the Minnesota Consortium for Autonomic Neuromodulation at University of Minnesota...

March 4, 2020

Executive Moves

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

Jean Gauvin Kane Biotech (TSX-V:KNE) appointed renowned Canadian veterinarian, Dr. Jean Gauvin, as its chief veterinary officer. Dr. Gauvin will serve as a liaison between Kane Biotech and industry; guide the company’s...

February 20, 2020

Executive Moves

Verona Pharma announces senior management changes

Verona Pharma (NASDAQ:VRNA) has appointed David Zaccardelli as president, CEO, and director; and Mark Hahn as CFO. Mr. Zaccardelli will replace current CEO, Jan-Anders Karlsson, who is retiring. Mr. Zaccardelli...

February 3, 2020

Executive Moves

ArcherDX names Mark Massaro as CFO

Mark Massaro Closely-held ArcherDX appointed research industry veteran, Mark Massaro, as its CFO. “Mark’s extensive knowledge of the diagnostics landscape, coupled with his more than 20 years of industry...

January 8, 2020

Executive Moves

Indalo appoints healthcare industry veteran Michael Heffernan as board chair

Closely-held Indalo Therapeutics appointed Michael Heffernan as chair of its board of directors. “Indalo’s unique approach to treating fibrosis, combined with a highly experienced team and world-class financial backers...

December 17, 2019

Executive Moves

Zenabis names Kevin Coft as interim CEO

Zenabis Global (TSX:ZENA) appointed Kevin Coft as interim CEO, effective immediately, replacing Andrew Grieve, whose contract was set to expire shortly. While Mr. Grieve will be returning to his investment business, he...

December 11, 2019

Executive Moves

Gerald Solensky resigns as Zomedica CEO; Shameze Rampertab named interim CEO

Gerald Solensky, Jr. has resigned as CEO, chairman and a director of Zomedica Pharmaceuticals (NYSE American, TSXV:ZOM), effective immediately. He will continue as a consultant to the company’s operating...

December 3, 2019

Category - Executive Moves

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Akcea names Damien Devitt as CEO

Covetrus names Benjamin Wolin as CEO

BioSig appoints John Osborn as consultant on autonomic neuromodulation

Renowned veterinarian, Dr. Jean Gauvin, joins Kane Biotech as chief veterinary officer

Verona Pharma announces senior management changes

ArcherDX names Mark Massaro as CFO

Indalo appoints healthcare industry veteran Michael Heffernan as board chair

Zenabis names Kevin Coft as interim CEO

Gerald Solensky resigns as Zomedica CEO; Shameze Rampertab named interim CEO

General

More